Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ASIC1 | P78348 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17777930 | 0.88 | KCNK3 (0.38) | KCNK3MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL25632913 | 0.86 | KCNK3 (0.37) | KCNK3MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL21451580 | 0.86 | ASIC1 (0.37) | KCNK3MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL17777971 | 0.85 | KCNK3 (0.39) | KCNK3MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL17777908 | 0.79 | ASIC1 (0.37) | KCNK3MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL17777810 | 0.78 | ASIC1 (0.36) | KCNK3MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL17777764 | 0.72 | PTGDR2 (0.42) | MEN1KMT2AALDH1A1MKNK2MAPT | |
| SCHEMBL17777768 | 0.71 | PTGDR2 (0.36) | KMT2ALMNAALDH1A1MKNK2MAPT | |
| SCHEMBL19659387 | 0.71 | CYP2D6 (0.34) | MEN1KMT2AALDH1A1MKNK2MAPT | |
| SCHEMBL22824585 | 0.69 | PTGDR2 (0.38) | MEN1KMT2ALMNAALDH1A1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233187-B2 | Fused bicyclic compounds for the treatment of disease | AKARNA THERAPEUTICS, LTD. (GB) | 2019-03-19 | — | — | US | disclosed |
| US-20170355699-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355699-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | KCNK3 4151/4885MEN1 285/4885KMT2A 1573/4885 |
| US-10233187-B2 | Fused bicyclic compounds for the treatment of disease | SLC10A1, VHL, GBA1 | KCNK3 2830/4885MEN1 302/4885KMT2A 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.